Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer

Launched by THE FIRST HOSPITAL OF JILIN UNIVERSITY · Jul 25, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating the effects of a treatment called HIPEC (Hyperthermic Intraperitoneal Chemotherapy) given after a type of surgery known as laparoscopic D2 radical surgery for patients with locally advanced gastric cancer. The goal is to see if this combination can help improve long-term survival for patients with specific stages of gastric adenocarcinoma, which is a type of stomach cancer. The trial is not yet recruiting participants, but it aims to ensure that the treatment is safe and beneficial for patients.

To be eligible for this trial, participants should be between 18 and 70 years old, have a confirmed diagnosis of gastric adenocarcinoma without any distant spread of cancer, and be suitable for surgery. It's important that they have not received any prior cancer treatments like chemotherapy or radiation. If you or someone you know fits these criteria and is interested in participating, you can expect to undergo a thorough evaluation, and if accepted, to receive the HIPEC treatment following the surgery. This study aims to gather valuable information that could help improve future treatments for gastric cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \>18 and ≤70 years;
• • 2. Male or nonpregnant female;
• • 3. Gastric adenocarcinoma cT3N+M0 and cT4aN+/-M0 (according to the 8th edition of the AJCC TNM staging system);
• • 4. No distant metastasis, suitable for D2 lymph node dissection;
• • 5. ECOG (Eastern Cooperative Oncology Group) performance status of 0-2;
• • 6. No prior cytotoxic chemotherapy, radiotherapy, or immunotherapy;
• • 7. Written informed consent given before any study-related procedures;
• Exclusion Criteria:
• • 1. Other cancers within the past 5 years;
• • 2. Distant metastasis (M1) found during surgery;
• • 3. ASA (American Society of Anesthesiologists) classification ≥IV and/or ECOG performance status \>2;
• • 4. Severe liver, kidney, cardiac, pulmonary, or coagulation dysfunction, or severe underlying diseases that make the patient unable to tolerate surgery;
• • 5. A history of severe mental illness;
• • 6. History of taking steroid medications;
• • 7. Receiving other chemotherapy, radiotherapy, or immunotherapy;
• • 8. Lack of written informed consent;